BCRX — BIOCRYST PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 882796 ·
Last close
$8.47
Market Cap
$2.16B
52W High
$11.22
52W Low
$6.00
ADV30
4,092,174
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 218,250,000 | 214,410,000 | 98,465,000 | 78,395,000 | 557,851,000 | 154,972,000 | 1,012,140,000 |
| Mar 2026 | 156,413,000 | 151,036,000 | -701,598,000 | -721,812,000 | 465,052,000 | 171,591,000 | 1,018,895,000 |
| Dec 2025 | 406,555,000 | 397,033,000 | 260,385,000 | 245,845,000 | 514,158,000 | 89,736,000 | 633,311,000 |
| Sep 2025 | 159,395,000 | 157,208,000 | 29,591,000 | 12,899,000 | 446,424,000 | 84,078,000 | 834,313,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$313,095,000
Investing CF
$-309,437,000
Financing CF
$62,092,000
CapEx
$-2,728,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.78
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,227,991,000
Inventory
$5,985,000
Receivables
$109,272,000
ST Investments
$66,809,000
EBIT TTM
$-379,018,000
Pretax Income TTM
$-454,175,000
Interest Exp TTM
$75,157,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$940,612,992
EBITDA
$433,047,008
Free Cash Flow
$323,666,752
Enterprise Value
$2,559,016,960
Total Cash
$352,572,992
Total Debt
$836,644,992
Shares Out
255,535,105
Trailing EPS
$-1.40
Book Value
$-1.78
ROE
—
ROA
52.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 874,837,000 | 340,989,000 | 263,861,000 | 514,158,000 | 633,311,000 | -119,153,000 | 347,369,000 |
| Dec 2024 | 450,712,000 | -2,543,000 | -88,881,000 | 490,420,000 | 966,354,000 | -475,934,000 | -52,020,000 |
| Dec 2023 | 331,412,000 | -103,709,000 | -226,539,000 | 516,960,000 | 972,488,000 | -455,528,000 | -95,141,000 |
| Dec 2022 | 270,827,000 | -148,435,000 | -247,116,000 | 550,000,000 | 844,597,000 | -294,597,000 | -161,850,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.94
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $8.00 · spot: $8.47 · call volume: 266 · put volume: 559
Expected Move to 2026-12-18:
±$1.59
(18.77%) —
implied range
$6.88 –
$10.06
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALVO | Alvotech | $2.19B | $6.15 | — |
| ADMA | ADMA BIOLOGICS, INC. | $2.27B | $10.12 | — |
| VCEL | Vericel Corp | $2.06B | $40.24 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.98B | $3.70 | — |
| MEOBF | MESOBLAST LTD | $2.47B | $1.90 | — |
News headlines (Yahoo Finance, 1h cache)
Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?
2026-09-23 10:26 · Yahoo
Biopharma Stock With Layers of Technical Support in Place
2026-09-21 18:44 · Yahoo
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
2026-09-19 02:01 · Yahoo
BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story
2026-09-14 16:10 · Yahoo
BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’
2026-09-10 15:52 · Yahoo
BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says
2026-09-10 15:42 · Yahoo
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease
2026-09-08 23:24 · Yahoo
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio
2026-09-08 20:45 · Yahoo
BioCryst to Present at Upcoming Investor Conference
2026-09-01 11:00 · Yahoo
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?
2026-08-31 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.